
NeuroPace (NPCE) Stock Forecast & Price Target
NeuroPace (NPCE) Analyst Ratings
Bulls say
NeuroPace Inc. has demonstrated substantial improvement in patient quality of life, as shown by a significant mean increase of 3.2 points on the QOLIE-89 survey following one year of treatment with the RNS system. The company's revenue growth has been robust, with a notable inflection seen in 2022, projecting a remarkable increase of 75.5% from 2022 to 2024. Furthermore, favorable macro trends, including a rise in the number of Comprehensive Epilepsy Centers and a 150% increase in epileptologists per capita from 2012 to 2019, indicate an expanding market and increasing awareness, which could drive further adoption of the RNS system.
Bears say
NeuroPace Inc. has been experiencing significant net losses and anticipates continued financial strain, with no clear path to achieving profitability in the near term. The necessity for additional capital to sustain operations presents challenges, as obtaining funding may prove difficult and could lead to unfavorable terms that impact business operations negatively. Furthermore, existing financial obligations and uncertainties regarding future guidance, along with competitive risks and potential dilution, exacerbate the company's precarious financial condition, contributing to a negative outlook on its stock performance.
This aggregate rating is based on analysts' research of NeuroPace and is not a guaranteed prediction by Public.com or investment advice.
NeuroPace (NPCE) Analyst Forecast & Price Prediction
Start investing in NeuroPace (NPCE)
Order type
Buy in
Order amount
Est. shares
0 shares